The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients

Clinical Rheumatology

Volumn 27, Issue 4, 2008, Pages 437-442

  Choi, Hyo Jin ^a   Shin, Young Kee ^c   Lee, Hyun Joo ^b   Kee, Joo Young ^b   Shin, Dong Woo ^b   Lee, Eun Young ^b   Lee, Yun Jong ^b   Lee, Eun Bong ^b   Song, Yeong Wook ^b  

^a Gachon University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

DLco; NT proBNP; Skin thickness; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CARBON MONOXIDE;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HUMAN; IMMUNOASSAY; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SKIN FIBROSIS; SKINFOLD THICKNESS; STATISTICAL MODEL; SYSTEMIC SCLEROSIS;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARBON MONOXIDE; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULMONARY ARTERY; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 40949147060     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0724-9     Document Type: Article

References (27)

1. MacGregor AJ, Canavan R, Knight C, Denton CP et al (2001) Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology (Oxford) 40:453-457
2. James SK, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease; GUSTO-IV substudy. Circulation 108:275-281
3. Fisher C, Berry C, Blue L, Morton JJ et al (2003) N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89:879-881
4. Kurose M, Yoshimura M, Yasue H (1997) Raised plasma BNP in a patient with acute pulmonary thromboembolism. Heart 78:320-321
5. Lainchbury JG, Campbell E, Frampton CM et al (2003) Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42:728-735
6. Wilkins MR, Redondo J, Brown LA (1997) The natriuretic peptide family. Lancet 349:1307-1310
7. Allanore Y, Borderie D, Meune C et al (2003) N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 48:3503-3508
8. Murkerjee D, Yap LB, Holmes AM et al (2003) Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Resp Med 97:1230-1236
9. Hesselstrand R, Ekman R, Eskilsson J et al (2005) Screening for pulmonary hypertension in systemic sclerosis; the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology 44:366-371
10. Dimitroulas T, Giannakoulas G, Karvounis H (2006) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121(1):135-137
11. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
12. LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15:202-205
13. Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289:2560-2572
14. Ooi GC, Mok MY, Tsang KWT et al (2003) Interstitial lung disease in systemic sclerosis an HRCT-clinical correlative study. Acta Radiologica 44:258-264
15. Remy-Jardin M, Giraud F, Remy J, Copin MC et al (1993) Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 189:693-698
16. Yeo KTJ, Wu AHB, Apple FS et al (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107-115
17. Hammerer-Lercher A, Neubauer E, Muller S et al (2001) Head-to head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310:193-197
18. Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:682-686
19. Rhew EY, Barr WG (2004) Scleroderma renal crisis: New insights and developments. Curr Rheumatol Rep 6:129-136
20. Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865-870
21. Morgan C, Knight C, Lunt M et al (2003) Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 62:146-150
22. Steen VD, Conte C, Owens GR et al (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283-1289
23. Steen VD, Graham G, Conte C et al (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35:765-770
24. Raymond I, Groenning BA, Hildebrandt PR et al (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro-brain natriuretic peptide in a large sample of the general population. Heart 89:745-751
25. Hobbs FDR, Davis RC, Roalfe AK et al (2002) Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure; cohort study in representative and high risk community populations. BMJ 324:1-5
26. Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6:257-260
27. Montagnana M, Lippi G, Volpe A et al (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39:913-917